

Manage Your Program:

HawaiiDerm2018



James Creg

University of Louisville [Sign out]

Wed Mar 7, 2018 03:51:24 PM

Reports List » Response Report

## Global Academy - Hawaii2018 - Demographic Survey

Likert Avg.  
**N/A**

Total Completed: 296

Options: Show Extended View

**Question 1.**

What is your area of practice?

Response	Count	Graph	Percent †
Dermatology	192		65%
Family Practice/General Practice	60		20%
Internal Medicine	12		4%
Pediatrics	6		2%
Other (View Responses)	27		9%
<b>Total Responses:</b>	<b>297</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 2.**

What is your primary practice setting?

Response	Count	Graph	Percent †
Solo Private Practice	60		20%
Group Private Practice	147		49%
Veterans Administration	1		< 1%
Indian Health Services	6		2%
Community/County Health Services	14		5%
Academic Medical Center	35		12%
Other (View Responses)	34		11%
<b>Total Responses:</b>	<b>297</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 3.**

How many years have you been in practice since completing residency or qualifying for practice?

Response	Count	Graph	Percent †
> 5 years	61		21%
5 - 10 years	47		16%
11 - 15 years	42		14%
16 - 20 years	36		12%
21 - 25 years	34		11%
26 - 30 years	23		8%
> 30 years	53		18%
<b>Total Responses:</b>	<b>296</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 4.**

On average, how many patients do you see each week?

Response	Count	Graph	Percent †
< 25	28		9%
26 - 50	32		11%
51 - 75	51		17%
76 - 100	66		22%
> 100	119		40%
<b>Total Responses:</b>	<b>296</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 5.**

What are the dermatologic diseases, conditions or disorders you see most frequently in your office?

Response	Count	Graph	Percent †
Open-ended Text Responses ( <a href="#">View Responses</a> )	248		100%
<i>Non-Responders:</i>	48		

**Legend****percent question responses**

Proportion of a specific response (Qa) to the sum of all responses provided for that question (Qt).

 $percent\ of\ total\ question\ responses = Qa / Qt$ 

(Example: X% of all responses to question Y were "A".)

† Percentages are calculated in three different ways. Click on the "Show Extended View" option at the top of the report to display the additional calculations. In cases where a question is required and only one response is allowed, all three percentages will be equal. The difference between the three calculations is most notable in a choose-all-that-apply question type that is optional.



Reports List » Response Report

**Global Academy - Hawaii2018 - Objectives Evaluation**

Likert Avg.  
**4.20**

Total Completed: 291

Options: Show Extended View

**This activity was created to address the professional practice gaps listed below:**

- Clinicians are not trained on the new treatments and approaches to common dermatologic diseases.
- Clinicians are not identifying new evidence for emerging theories on the pathophysiologies of various types of psoriasis, including treatment plans for appropriate patient selection, screening, and protocols for identifying comorbid conditions.
- Clinicians are not identifying and prescribing newer biologics for complex dermatologic disorders.
- Learners are not recognizing the benefits of emerging treatments such as retinoids, antibiotic/immunomodulatory agents, combination agents, and laser/light techniques for acne and rosacea.
- Dermatologists and other clinicians are not recognizing and treating melanoma early enough as evidenced by the alarming prevalence of this condition.
- Dermatologists are not identifying the benefits and limitations of surgical and nonsurgical techniques as well as topical treatment options for aesthetic dermatology.

**Question 1.**

Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

Participating in this educational activity changed your **KNOWLEDGE** in the professional practice gaps listed above.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.347		± 0.818
Response	Count	Graph	Percent †
1=Strongly Disagree	3		1%
2	4		1%
3	34		12%
4	98		34%
5=Strongly Agree	152		52%
<b>Total Responses:</b>	<b>291</b>		

[Respondent Details](#) [Trend Analysis](#)

Participating in this educational activity changed your **COMPETENCE** in the professional practice gaps listed above.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.192		± 0.912
Response	Count	Graph	Percent †
1=Strongly Disagree	6		2%
2	6		2%
3	44		15%
4	105		36%
5=Strongly Agree	130		45%
<b>Total Responses:</b>	<b>291</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Participating in this educational activity changed your **PERFORMANCE** in the professional practice gaps listed above.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.148		± 0.900
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	6		2%
3	51		18%
4	108		37%
5=Strongly Agree	121		42%
<b>Total Responses:</b>	<b>291</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

**Question 2.**

Please elaborate on your answer(s).

Response	Count	Graph	Percent †
Open-ended Text Responses <a href="#">(View Responses)</a>	152		100%
<i>Non-Responders:</i>	139		

**Question 3.**

Having completed this activity, you are better able to:

Integrate into daily practice evidence based recommendations on new and emerging therapies for common dermatologic diseases

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.345		± 0.814
Response	Count	Graph	Percent †
1=Strongly Disagree	3		1%
2	5		2%
3	28		10%
4	101		36%
5=Strongly Agree	144		51%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Implement updated strategies for managing acne, rosacea, atopic dermatitis, contact dermatitis and actinic keratosis  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.349		± 0.806
Response	Count	Graph	Percent †
1=Strongly Disagree	4		1%
2	3		1%
3	26		9%
4	106		38%
5=Strongly Agree	142		51%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Explain the roles of currently available biologic agents in the treatment of psoriasis and psoriatic arthritis, and appropriately incorporate newer biologics into therapeutic practice as these become available.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.260		± 0.910
Response	Count	Graph	Percent †
1=Strongly Disagree	4		1%
2	9		3%
3	38		14%

4	89		32%
5=Strongly Agree	141		50%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>10</i>		

Describe the mechanisms of action, efficacy, and safety of the biologic agents used to treat psoriasis, as well as the factors involved in appropriate patient selection.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.196		± 0.895
Response	Count	Graph	Percent †
1=Strongly Disagree	4		1%
2	8		3%
3	42		15%
4	102		36%
5=Strongly Agree	125		44%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>10</i>		

Assess patients for comorbidities and manage psoriasis as well as associated comorbidities.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.238		± 0.872
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	4		1%
3	39		14%
4	104		37%
5=Strongly Agree	129		46%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>10</i>		

Compare treatment options for hidradenitis suppurativa.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.224		± 0.855
Response	Count	Graph	Percent †
1=Strongly Disagree	4		1%
2	7		2%
3	33		12%
4	115		41%
5=Strongly Agree	122		43%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Diagnose and manage patients with vitiligo.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.153		± 0.875
Response	Count	Graph	Percent †
1=Strongly Disagree	4		1%
2	7		2%
3	44		16%
4	113		40%
5=Strongly Agree	113		40%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Describe the pathophysiology of keloids.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.246		± 0.841
Response	Count	Graph	Percent †
1=Strongly Disagree	4		1%
2	4		1%
3	37		13%

4	110		39%
5=Strongly Agree	126		45%
<b>Total Responses:</b>	<b>281</b>	Respondent Details Trend Analysis	
<i>Non-Responders:</i>	<i>10</i>		

Develop a strategy for the optimal management of atopic dermatitis, including rotational regimen.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.306		± 0.792
Response	Count	Graph	Percent †
1=Strongly Disagree	3		1%
2	3		1%
3	31		11%
4	112		40%
5=Strongly Agree	132		47%
<b>Total Responses:</b>	<b>281</b>	Respondent Details Trend Analysis	
<i>Non-Responders:</i>	<i>10</i>		

Describe the rationales and mechanisms of action of the new and emerging therapies for atopic dermatitis, particularly the recently approved and emerging agents.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.285		± 0.835
Response	Count	Graph	Percent †
1=Strongly Disagree	3		1%
2	5		2%
3	36		13%
4	102		36%
5=Strongly Agree	135		48%
<b>Total Responses:</b>	<b>281</b>	Respondent Details Trend Analysis	
<i>Non-Responders:</i>	<i>10</i>		

Analyze treatment approaches for the pediatric patient with common as well as complex skin diseases.  
(1=Strongly Disagree,5=Strongly Agree)





Sample	Mean	Graph	Std. Dev.
All Respondents	4.164		± 0.846
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	9		3%
3	42		15%
4	116		41%
5=Strongly Agree	112		40%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Incorporate the recent research advances in understanding and treating pediatric dermatology issues such as atopic dermatitis and pediatric acne.  
 (1=Strongly Disagree,5=Strongly Agree)







Sample	Mean	Graph	Std. Dev.
All Respondents	4.167		± 0.872
Response	Count	Graph	Percent †
1=Strongly Disagree	3		1%
2	9		3%
3	42		15%
4	111		40%
5=Strongly Agree	116		41%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Discuss new approaches to therapy including pathway targeted therapy in the treatment of melanoma.  
 (1=Strongly Disagree,5=Strongly Agree)







Sample	Mean	Graph	Std. Dev.
All Respondents	4.199		± 0.884
Response	Count	Graph	Percent †
1=Strongly Disagree	4		1%
2	8		3%
3	39		14%

4	107		38%
5=Strongly Agree	123		44%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Assess the role of diagnostic tools and technology in diagnosis and detection of skin cancers.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.295		± 0.833
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	2		< 1%
3	32		11%
4	108		38%
5=Strongly Agree	134		48%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Recognize the factors that are important in selecting appropriate filler agents for treating different areas of the face and targeted planar depths.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.021		± 1.049
Response	Count	Graph	Percent †
1=Strongly Disagree	11		4%
2	10		4%
3	55		20%
4	91		32%
5=Strongly Agree	114		41%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Compare and contrast the efficacy and safety of agents, devices, and techniques currently available in aesthetic and

procedural dermatology.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.036		± 1.021
Response	Count	Graph	Percent †
1=Strongly Disagree	9		3%
2	9		3%
3	60		21%
4	88		31%
5=Strongly Agree	115		41%
<b>Total Responses:</b>	<b>281</b>	Respondent Details Trend Analysis	
<i>Non-Responders:</i>	<i>10</i>		

Determine the appropriate nonsurgical techniques for facial rejuvenation based on an enhanced understanding of facial anatomy.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.046		± 1.001
Response	Count	Graph	Percent †
1=Strongly Disagree	8		3%
2	12		4%
3	50		18%
4	100		36%
5=Strongly Agree	111		40%
<b>Total Responses:</b>	<b>281</b>	Respondent Details Trend Analysis	
<i>Non-Responders:</i>	<i>10</i>		

Examine energy-based technology for body contouring and discuss appropriate patient selection criteria for utilizing these devices.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	3.996		± 1.033
Response	Count	Graph	Percent †
1=Strongly Disagree	9		3%

2	13		5%
3	57		20%
4	93		33%
5=Strongly Agree	109		39%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Evaluate the role of dermoscopy in clinical practice and demonstrate enhanced skill in using this technique to diagnose dermatologic disorders  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.221		± 0.957
Response	Count	Graph	Percent †
1=Strongly Disagree	8		3%
2	6		2%
3	38		14%
4	93		33%
5=Strongly Agree	136		48%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Analyze emerging treatments for onychomycosis.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.278		± 0.837
Response	Count	Graph	Percent †
1=Strongly Disagree	4		1%
2	4		1%
3	34		12%
4	107		38%
5=Strongly Agree	132		47%
<b>Total Responses:</b>	<b>281</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

**Legend****percent question responses**

Proportion of a specific response ( $Qa$ ) to the sum of all responses provided for that question ( $Qt$ ).

*percent of total question responses =  $Qa / Qt$*

(Example: X% of all responses to question Y were "A".)

† Percentages are calculated in three different ways. Click on the "Show Extended View" option at the top of the report to display the additional calculations. In cases where a question is required and only one response is allowed, all three percentages will be equal. The difference between the three calculations is most notable in a choose-all-that-apply question type that is optional.



Reports List » Response Report

**Global Academy - Hawaii2018 - Speaker Evaluation**

Likert Avg.  
**4.51**

Total Completed: 288

Options: Show Extended View

**Question 1.**

Please evaluate the effectiveness of the presenting faculty in improving your knowledge, competence and/or performance.

Hilary E. Baldwin, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.640		± 0.589
Response	Count	Graph	Percent †
1=Poor	0		0%
2	1		< 1%
3	13		5%
4	71		26%
5=Excellent	193		69%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>10</i>		

Vincent Bertucci, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.496		± 0.684
Response	Count	Graph	Percent †
1=Poor	1		< 1%
2	1		< 1%
3	21		8%
4	91		33%
5=Excellent	164		59%

<b>Total Responses:</b>	<b>278</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>
<i>Non-Responders:</i>	<i>10</i>		

Clara N. Curiel, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.450		± 0.718
Response	Count	Graph	Percent †
1=Poor	1		< 1%
2	3		1%
3	22		8%
4	96		35%
5=Excellent	156		56%
<b>Total Responses:</b>	<b>278</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>
<i>Non-Responders:</i>	<i>10</i>		

Mark D. P. Davis, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.543		± 0.627
Response	Count	Graph	Percent †
1=Poor	0		0%
2	1		< 1%
3	17		6%
4	90		32%
5=Excellent	170		61%
<b>Total Responses:</b>	<b>278</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>
<i>Non-Responders:</i>	<i>10</i>		

Lawrence F. Eichenfield, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
--------	------	-------	-----------

Response	Count	Graph	Percent †
All Respondents	4.608		± 0.625
1=Poor	0		0%
2	1		< 1%
3	18		6%
4	70		25%
5=Excellent	189		68%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Laura K. Ferris, MD, PhD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.496		± 0.699
Response	Count	Graph	Percent †
1=Poor	1		< 1%
2	2		< 1%
3	21		8%
4	88		32%
5=Excellent	166		60%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Linda F. Stein Gold, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.597		± 0.655
Response	Count	Graph	Percent †
1=Poor	1		< 1%
2	2		< 1%
3	14		5%
4	74		27%
5=Excellent	187		67%



<b>Total Responses:</b>	<b>278</b>	Respondent Details Trend Analysis
<i>Non-Responders:</i>	<i>10</i>	

Kenneth B. Gordon, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.496		± 0.710
Response	Count	Graph	Percent †
1=Poor	1		< 1%
2	2		< 1%
3	23		8%
4	84		30%
5=Excellent	168		60%
<b>Total Responses:</b>	<b>278</b>	Respondent Details Trend Analysis	
<i>Non-Responders:</i>	<i>10</i>		

Jeremy B. Green, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.453		± 0.698
Response	Count	Graph	Percent †
1=Poor	1		< 1%
2	1		< 1%
3	24		9%
4	97		35%
5=Excellent	155		56%
<b>Total Responses:</b>	<b>278</b>	Respondent Details Trend Analysis	
<i>Non-Responders:</i>	<i>10</i>		

Iltefat H. Hamzavi, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.489		± 0.673

Response	Count	Graph	Percent †
1=Poor	0		0%
2	3		1%
3	19		7%
4	95		34%
5=Excellent	161		58%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>10</i>		

George J. Hruza, MD, MBA  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.356		± 0.841
Response	Count	Graph	Percent †
1=Poor	5		2%
2	5		2%
3	21		8%
4	102		37%
5=Excellent	145		52%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>10</i>		

Jennifer Huang, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.500		± 0.710
Response	Count	Graph	Percent †
1=Poor	1		< 1%
2	2		< 1%
3	23		8%
4	83		30%
5=Excellent	169		61%

<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>
<i>Non-Responders:</i>	<i>10</i>	

Michael S. Kaminer, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.428		± 0.736
Response	Count	Graph	Percent †
1=Poor	1		< 1%
2	3		1%
3	26		9%
4	94		34%
5=Excellent	154		55%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>10</i>		

Suzanne L. Kilmner, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.475		± 0.683
Response	Count	Graph	Percent †
1=Poor	0		0%
2	3		1%
3	21		8%
4	95		34%
5=Excellent	159		57%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>10</i>		

Craig L. Leonardi, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.522		± 0.683

Response	Count	Graph	Percent †
1=Poor	0		0%
2	4		1%
3	18		6%
4	85		31%
5=Excellent	171		62%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>10</i>		

Moise L. Levy, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.529		± 0.662
Response	Count	Graph	Percent †
1=Poor	0		0%
2	2		< 1%
3	20		7%
4	85		31%
5=Excellent	171		62%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>10</i>		

Ashfaq A. Marghoob, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.658		± 0.620
Response	Count	Graph	Percent †
1=Poor	0		0%
2	2		< 1%
3	16		6%
4	57		21%
5=Excellent	203		73%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Non-Responders:	10
-----------------	----

Natasha A. Mesinkovska, MD, PhD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.522		± 0.734
Response	Count	Graph	Percent †
1=Poor	1		< 1%
2	3		1%
3	25		9%
4	70		25%
5=Excellent	179		64%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
Non-Responders:	10		

Kishwer S. Nehal, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.500		± 0.662
Response	Count	Graph	Percent †
1=Poor	0		0%
2	2		< 1%
3	20		7%
4	93		33%
5=Excellent	163		59%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
Non-Responders:	10		

Theodore Rosen, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.633		± 0.649

Response	Count	Graph	Percent †
1=Poor	1		< 1%
2	1		< 1%
3	17		6%
4	61		22%
5=Excellent	198		71%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Mark G. Rubin, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.507		± 0.689
Response	Count	Graph	Percent †
1=Poor	1		< 1%
2	1		< 1%
3	22		8%
4	86		31%
5=Excellent	168		60%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Roberta D. Senglemann, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.493		± 0.694
Response	Count	Graph	Percent †
1=Poor	1		< 1%
2	1		< 1%
3	23		8%
4	88		32%
5=Excellent	165		59%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Brooke Sikora, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.486		± 0.678
Response	Count	Graph	Percent †
1=Poor	0		0%
2	1		< 1%
3	26		9%
4	88		32%
5=Excellent	163		59%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Robert A. Silverman, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.543		± 0.627
Response	Count	Graph	Percent †
1=Poor	0		0%
2	1		< 1%
3	17		6%
4	90		32%
5=Excellent	170		61%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Eric L. Simpson, MD, MCR  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.532		± 0.661
Response	Count	Graph	Percent †

1=Poor	0		0%
2	2		< 1%
3	20		7%
4	84		30%
5=Excellent	172		62%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Erik J. Stratman, MD  
(1=Poor,5=Excellent)







Sample	Mean	Graph	Std. Dev.
All Respondents	4.450		± 0.666
Response	Count	Graph	Percent †
1=Poor	0		0%
2	2		< 1%
3	21		8%
4	105		38%
5=Excellent	150		54%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		

Jashin Wu, MD  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.428		± 0.721
Response	Count	Graph	Percent †
1=Poor	1		< 1%
2	3		1%
3	23		8%
4	100		36%
5=Excellent	151		54%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	10		



Christopher B. Zachary, FRCP  
(1=Poor,5=Excellent)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.496		± 0.694
Response	Count	Graph	Percent †
1=Poor	0		0%
2	3		1%
3	23		8%
4	85		31%
5=Excellent	167		60%
<b>Total Responses:</b>	<b>278</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>10</i>		


## PHARMACISTS ONLY

Please record your attendance at the conference by answering the following questions.

If you are not a pharmacist, skip these questions.


### Question 2.

Did you attend all **The Future of Medical Dermatology Part I - Morning** presentations on **Sunday, February 4th**?



Response	Count	Graph	Percent †
Yes	111		84%
No	21		16%
<b>Total Responses:</b>	<b>132</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>156</i>		

### Question 3.



Did you attend all **The Future of Medical Dermatology Part I - Afternoon** presentations on **Sunday, February 4th**?

Response	Count	Graph	Percent †
Yes	101		80%
No	26		20%
<b>Total Responses:</b>	<b>127</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	<i>161</i>		



**Question 4.**Did you attend all **The Future of Medical Dermatology Part II - Morning Sessions** on **Monday, February 5th**?

Response	Count	Graph	Percent †
Yes	113		90%
No	12		10%
<b>Total Responses:</b>	<b>125</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	163		



**Question 5.**Did you attend all **The Future of Medical Dermatology Part II - Afternoon Sessions** on **Monday, February 5th**?

Response	Count	Graph	Percent †
Yes	106		85%
No	18		15%
<b>Total Responses:</b>	<b>124</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	164		

**Question 6.**Did you attend all **Aesthetic and Procedural Dermatology Part I** presentations on **Tuesday, February 6th**?



Response	Count	Graph	Percent †
Yes	91		72%
No	35		28%
<b>Total Responses:</b>	<b>126</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	162		

**Question 7.**Did you attend all **Clinical Update on Pediatric Dermatology** presentations on **Wednesday, February 7th**?

Response	Count	Graph	Percent †
Yes	113		90%
No	13		10%
<b>Total Responses:</b>	<b>126</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	
<i>Non-Responders:</i>	162		

**Question 8.**Did you attend all **Melanoma and Cutaneous Oncology** presentations on **Friday, February 8th**?

Response	Count	Graph	Percent †
----------	-------	-------	-----------

Yes	107		87%
No	16		13%
<b>Total Responses:</b>	<b>123</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>
<i>Non-Responders:</i>	<i>165</i>		

**Legend**



**percent question responses**

Proportion of a specific response (*Qa*) to the sum of all responses provided for that question (*Qt*).

*percent of total question responses = Qa / Qt*

(Example: X% of all responses to question Y were "A".)

† Percentages are calculated in three different ways. Click on the "Show Extended View" option at the top of the report to display the additional calculations. In cases where a question is required and only one response is allowed, all three percentages will be equal. The difference between the three calculations is most notable in a choose-all-that-apply question type that is optional.

Manage Your Program:

HawaiiDerm2018



James Creg

University of Louisville [Sign out]

Wed Mar 7, 2018 03:54:00 PM

Reports List » Response Report

## Global Academy - July 2016 Revised Shared Rutgers Activity Evaluation

 Likert Avg.  
**4.35**

Total Completed: 287

Options: Show Extended View

### Question 1.

Based on the content of the activity, what will you do differently in the care of your patients and/or regarding your professional responsibilities? (Select one)

Response	Count	Graph	Percent †
Implement a change in my practice/workplace.	97		34%
Seek additional information on this topic.	53		18%
Implement a change in my practice/workplace and seek additional information on this topic.	82		29%
Do nothing differently. Current practice/job responsibilities reflect activity recommendations.	49		17%
Do nothing differently. Content was not convincing.	0		0%
Do nothing differently. System barriers prevent me from changing my practice/workplace.	6		2%
<b>Total Responses:</b>	<b>287</b>		

[Respondent Details](#) [Trend Analysis](#)

### Question 2.

If you anticipate changing one or more aspects of your practice and/or professional responsibilities as a result of your participation in this activity, please briefly describe how you plan to do so.

Response	Count	Graph	Percent †
Open-ended Text Responses <a href="#">(View Responses)</a>	142		100%
<i>Non-Responders:</i>	145		

### Question 3.

If you plan to change your practice/professional responsibilities, may we contact you in 2 months to see how you are progressing?



Response	Count	Graph	Percent †
Yes	76		26%
No	154		54%
I don't plan to make a change	57		20%

Total Responses:

287

[Respondent Details](#) [Trend Analysis](#)**Question 4.**


Were the patient recommendations based on acceptable practices in medicine?

Response	Count	Graph	Percent †
Yes	287		100%
No	0		0%
<b>Total Responses:</b>	<b>287</b>		

[Respondent Details](#) [Trend Analysis](#)



**Question 5.**

If no, please explain which recommendation(s) were not based on acceptable practices in medicine.

Response	Count	Graph	Percent †
Open-ended Text Responses ( <a href="#">View Responses</a> )	7		100%
<i>Non-Responders:</i>	280		

**Question 6.**


Do you think the presentations were without commercial bias and influence?

Response	Count	Graph	Percent †
Yes	269		94%
No	18		6%
<b>Total Responses:</b>	<b>287</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 7.**

If no, please list the presentation(s) that were biased.

Response	Count	Graph	Percent †
Open-ended Text Responses ( <a href="#">View Responses</a> )	21		100%
<i>Non-Responders:</i>	266		

**Question 8.**

The presentations met my educational needs by:

This education increased my understanding of the subject.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.

Response	Count	Graph	Percent †
All Respondents	4.547		± 0.677
1=Strongly Disagree	2		< 1%
2	1		< 1%
3	15		5%
4	89		31%
5=Strongly Agree	180		63%
<b>Total Responses:</b>	<b>287</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

This education will influence how I do my job.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.307		± 0.830
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	6		2%
3	38		13%
4	97		34%
5=Strongly Agree	144		50%
<b>Total Responses:</b>	<b>287</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

This education will help me improve my job performance.  
 (1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.369		± 0.791
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	5		2%
3	29		10%
4	100		35%
5=Strongly Agree	151		53%
<b>Total Responses:</b>	<b>287</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

This education will help me collaborate with other healthcare professionals.  
 (1=Strongly Disagree,5=Strongly Agree)




Sample	Mean	Graph	Std. Dev.
All Respondents	4.244		± 0.922
Response	Count	Graph	Percent †
1=Strongly Disagree	4		1%
2	9		3%
3	44		15%
4	86		30%
5=Strongly Agree	144		50%
<b>Total Responses:</b>	<b>287</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

This education addressed issues in cultural competency.  
 (1=Strongly Disagree,5=Strongly Agree)







Sample	Mean	Graph	Std. Dev.
All Respondents	3.930		± 1.052
Response	Count	Graph	Percent †
1=Strongly Disagree	9		3%
2	15		5%
3	70		24%
4	86		30%
5=Strongly Agree	107		37%
<b>Total Responses:</b>	<b>287</b>		<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>

This education was educationally sound and scientifically balanced.  
 (1=Strongly Disagree,5=Strongly Agree)







Sample	Mean	Graph	Std. Dev.
All Respondents	4.491		± 0.761
Response	Count	Graph	Percent †
1=Strongly Disagree	3		1%
2	3		1%

3	20		7%
4	85		30%
5=Strongly Agree	176		61%
<b>Total Responses:</b>	<b>287</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

This education was free of commercial bias or influence  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.328		± 0.930
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	10		3%
3	32		11%
4	79		28%
5=Strongly Agree	161		56%
<b>Total Responses:</b>	<b>287</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

This education met my expectations.  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.512		± 0.766
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	5		2%
3	21		7%
4	75		26%
5=Strongly Agree	184		64%
<b>Total Responses:</b>	<b>287</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

**Question 9.**

This activity should improve my:

Medical or Practice Knowledge



(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.551		± 0.702
Response	Count	Graph	Percent †
1=Strongly Disagree	2		< 1%
2	2		< 1%
3	17		6%
4	81		28%
5=Strongly Agree	185		64%
<b>Total Responses:</b>	<b>287</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Care Attitudes

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.157		± 0.950
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	10		3%
3	50		17%
4	92		32%
5=Strongly Agree	130		45%
<b>Total Responses:</b>	<b>287</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

Procedural or Cognitive Skills

(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.355		± 0.793
Response	Count	Graph	Percent †
1=Strongly Disagree	1		< 1%
2	7		2%
3	30		10%
4	100		35%

5=Strongly Agree	149		52%
<b>Total Responses:</b>	<b>287</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

**Practice Behavior**  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.251		± 0.889
Response	Count	Graph	Percent †
1=Strongly Disagree	5		2%
2	5		2%
3	41		14%
4	98		34%
5=Strongly Agree	138		48%
<b>Total Responses:</b>	<b>287</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

**Patients' Clinical Outcomes**  
(1=Strongly Disagree,5=Strongly Agree)

Sample	Mean	Graph	Std. Dev.
All Respondents	4.359		± 0.789
Response	Count	Graph	Percent †
1=Strongly Disagree	1		< 1%
2	6		2%
3	32		11%
4	98		34%
5=Strongly Agree	150		52%
<b>Total Responses:</b>	<b>287</b>	<a href="#">Respondent Details</a> <a href="#">Trend Analysis</a>	

**Question 10.**

Please indicate any primary barriers to implementing information acquired at the event to updating and/or redefining your patient care approach? (choose all that apply)

Response	Count	Graph	Percent †
Diagnostic tool/treatment limitation.	68		15%
Diagnostic tool/treatment unavailability.	82		19%

Patients decline diagnostic or treatment intervention.	43		10%
I don't feel confident in implementing this change.	18		4%
Lack of patient education.	32		7%
My practice doesn't permit this type of change.	36		8%
Lack of time to implement	41		9%
I need more education about this topic.	61		14%
Other (View Responses)	60		14%
<b>Total Responses:</b>	<b>441</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 11.**

How do you think these barriers could be eliminated?

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	287		100%

**Question 12.**

Please rate on a scale of 1 to 5.

(1=Poor, 2=Fair, 3=Average, 4=Good, 5=Excellent)

How would you rate this activity?  
(1=Poor,5=Excellent)


Sample	Mean	Graph	Std. Dev.
All Respondents	4.519		± 0.694
Response	Count	Graph	Percent †
1=Poor	1		< 1%
2	2		< 1%
3	21		7%
4	86		30%
5=Excellent	177		62%
<b>Total Responses:</b>	<b>287</b>		

[Respondent Details](#) [Trend Analysis](#)

**Question 13.**


What issues are you experiencing in your practice/regarding your professional responsibilities that could be addressed in future programming?

Response	Count	Graph	Percent †
----------	-------	-------	-----------

Open-ended Text Responses (View Responses)	109		100%
<i>Non-Responders:</i>	178		

**Question 14.**

Please provide us with any additional comments you would like to make including suggestions for improvement. We welcome your feedback.

Response	Count	Graph	Percent †
Open-ended Text Responses (View Responses)	97		100%
<i>Non-Responders:</i>	190		

**Legend****percent question responses**

Proportion of a specific response ( $Qa$ ) to the sum of all responses provided for that question ( $Qt$ ).

$percent\ of\ total\ question\ responses = Qa / Qt$

(Example: X% of all responses to question Y were "A".)

† Percentages are calculated in three different ways. Click on the "Show Extended View" option at the top of the report to display the additional calculations. In cases where a question is required and only one response is allowed, all three percentages will be equal. The difference between the three calculations is most notable in a choose-all-that-apply question type that is optional.